Study reinvestigates benefit of biomarker tests in certain breast cancer patients
 

The German Institute for Quality and Efficiency in Health Care reinvestigated the benefit of biomarker tests to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, that is, women with primary hormone receptor-positive, HER2/neu-negative breast cancer and 0 to 3 affected lymph nodes.

More...